RxDoctor Payments Data

Hida Nierenburg, MD

Neurology · Poughkeepsie, NYNPI 1821314766

Payments from drug & device makers

$297,250in general payments, 2019–2025

Across 715 payments — averaging $415.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$110K
  • Amgen$60K
  • Ipsen Innovation$58K
  • Pfizer$24K
  • Teva Pharmaceuticals USA, Inc.$24K
  • Biohaven Pharmaceuticals, Inc.$14K
  • plus $7K from 21 others

What the payments were for

  • Consulting fees$2,5632%
  • Speaking & faculty fees$133,15684%
  • Travel & lodging$4,0833%
  • Food & beverage$17,97211%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$297,250 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$249,873
Medicare patients
369
Services billed
18,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate114$189,640
UbrelvyUbrogepant130$179,127
QuliptaAtogepant100$116,411
Aimovig AutoinjectorErenumab-Aooe61$53,516
Emgality PenGalcanezumab-Gnlm61$45,571
Emgality SyringeGalcanezumab-Gnlm23$19,487
Ajovy AutoinjectorFremanezumab-Vfrm13$10,112
Eletriptan HbrEletriptan Hydrobromide53$6,154
Acetazolamide ErAcetazolamide11$2,757
Gabapentin165$2,424
Sumatriptan Succinate100$1,715
RizatriptanRizatriptan Benzoate56$1,510
Naratriptan Hcl25$1,458
Nortriptyline Hcl36$743
Indomethacin17$678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$109,568$295,538230 claims
PfizerNurtec Odt$24,422$189,640114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →